Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Clinical trial NCT05495724 · UNKNOWN
Trial details
- NCT number
- NCT05495724
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-23
- Primary completion
- 2025-02-01
- Enrollment
- 176
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.